top of page

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

  • Writer: ANAVEX® Life Sciences Corp.
    ANAVEX® Life Sciences Corp.
  • May 11, 2011
  • 1 min read

Expert Opin Ther Targets. 2011 May ; 15(5): 557–577. doi:10.1517/14728222.2011.560837.

Hayashi Teruo*, Tsai Shang-Yi, Mori Tomohisa, Fujimoto Michiko, and Su Tsung-Ping


 
 
bottom of page